Prevencio announced today that patient data demonstrate high accuracy with its artificial intelligence (AI)-driven HART CVE blood test.
Kirkland, Washington-based Prevencio presented data at last week’s American College of Cardiology (ACC) Scientific Sessions that suggested that the HART CVE blood test significantly improves the risk classification for patients with diabetes, allowing for more aggressive therapy in higher-risk patients and avoiding expensive or invasive treatment for patients at a lower risk.
The study, run by cardiologists at Massachusetts General Hospital, observed 450 patients to predict the one-year risk of heart attack, stroke or cardiovascular death in patients with diabetes. With the test score divided into low-risk and high-risk categories, the test showed a highly accurate hazard ratio (HR) of 25, demonstrating that a high-risk patient with diabetes has 25 times the risk for a major cardiac event within one year compared to low-risk patients without diabetes.
Mass General practicing cardiologist and principal investigator in the development, validation, and ongoing testing of the HART CVE test, Dr. James L. Januzzi, said in a news release that the test could, in addition to aiding in the care of patients with diabetes, play a role in improving pharmaceutical cardiac clinical trials.
“Prevencio is grateful for our collaboration with Massachusetts General Hospital, and we look forward to ongoing improvement in patient care,” Prevencio President and CEO Rhonda Rhyne said in the release. “Our mission is to provide clinicians with safer, more accurate, and more affordable ways to identify and treat the tens of millions of patients with diabetes and cardiac issues.”